Intelligence Driven Advisers LLC Sells 755 Shares of DexCom, Inc. (NASDAQ:DXCM)

Intelligence Driven Advisers LLC reduced its position in DexCom, Inc. (NASDAQ:DXCM) by 12.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,237 shares of the medical device company’s stock after selling 755 shares during the quarter. Intelligence Driven Advisers LLC’s holdings in DexCom were worth $636,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of DXCM. Winslow Capital Management LLC purchased a new stake in DexCom in the third quarter valued at approximately $173,120,000. Vaughan Nelson Investment Management L.P. raised its stake in DexCom by 16,943.0% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 1,459,730 shares of the medical device company’s stock valued at $136,193,000 after purchasing an additional 1,451,165 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in shares of DexCom by 79.3% during the third quarter. Westfield Capital Management Co. LP now owns 1,847,865 shares of the medical device company’s stock worth $172,406,000 after acquiring an additional 817,351 shares in the last quarter. TimesSquare Capital Management LLC raised its stake in shares of DexCom by 11,359.1% during the third quarter. TimesSquare Capital Management LLC now owns 733,380 shares of the medical device company’s stock worth $68,424,000 after acquiring an additional 726,980 shares in the last quarter. Finally, Natixis Advisors L.P. raised its stake in shares of DexCom by 141.4% during the fourth quarter. Natixis Advisors L.P. now owns 1,129,570 shares of the medical device company’s stock worth $140,168,000 after acquiring an additional 661,584 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insider Transactions at DexCom

In other news, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the transaction, the executive vice president now owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the transaction, the executive vice president now owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 14,639 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total value of $1,967,627.99. Following the completion of the transaction, the chief operating officer now directly owns 273,913 shares of the company’s stock, valued at approximately $36,816,646.33. The disclosure for this sale can be found here. Insiders sold a total of 189,375 shares of company stock valued at $25,530,859 in the last quarter. 0.41% of the stock is owned by insiders.

DexCom Stock Up 0.3 %

Shares of DXCM stock traded up $0.33 during mid-day trading on Thursday, reaching $126.21. 1,104,152 shares of the company’s stock traded hands, compared to its average volume of 3,031,521. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The company has a market cap of $50.19 billion, a P/E ratio of 80.84, a P/E/G ratio of 2.18 and a beta of 1.23. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The company’s 50-day moving average price is $131.68 and its 200-day moving average price is $119.57.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. On average, equities analysts expect that DexCom, Inc. will post 1.77 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on DXCM. Canaccord Genuity Group lifted their price target on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. UBS Group raised their target price on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a report on Wednesday. Citigroup raised their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, Raymond James raised their target price on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $141.67.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.